Population pharmacokinetics of mycophenolic acid in pediatric renal transplant patients using parametric and nonparametric approaches

被引:32
|
作者
Premaud, A.
Weber, L. T. [2 ]
Toenshoff, B. [3 ]
Armstrong, V. W. [4 ]
Oellerich, M. [4 ]
Urien, S. [5 ,6 ]
Marquet, P. [7 ]
Rousseau, A. [1 ,8 ]
机构
[1] Univ Limoges, Fac Med, Lab Clin Pharmacol, INSERM,U850, F-87025 Limoges, France
[2] Univ Munich, Univ Childrens Hosp, Munich, Germany
[3] Univ Childrens Hosp, D-69120 Heidelberg, Germany
[4] Univ Med Ctr Gottingen, Dept Clin Chem, Gottingen, Germany
[5] Univ Paris 05, INSERM, CIC 0901, Paris, France
[6] Univ Paris 05, EA 3620, Paris, France
[7] CHU Limoges, Dept Pharmacol & Toxicol, Limoges, France
[8] Univ Limoges, Fac Pharm, Dept Biomath, F-87025 Limoges, France
关键词
Mycophenolic acid; Pediatric; Renal transplantation; Population pharmacokinetics; Parametric; Nonparametric; UNDER-THE-CURVE; LIMITED SAMPLING STRATEGY; BAYESIAN-ESTIMATION; ENTEROHEPATIC CIRCULATION; MOFETIL SUSPENSION; RECIPIENTS; AREA; CYCLOSPORINE; MODEL; PERFORMANCE;
D O I
10.1016/j.phrs.2010.10.017
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Mycophenolic acid (MPA) is an immunosuppressive drug widely used in the prevention of acute rejection in pediatric renal transplant recipients and is characterized by a wide inter-individual variability in its pharmacokinetics. The aim of this study was to compare population pharmacokinetic modeling of MPA in pediatric renal transplant recipients given mycophenolate mofetil, the ester prodrug of MPA, using parametric and nonparametric population methods. The data from 34 pediatric renal transplants (73 full pharmacokinetic profiles obtained on day 21, months 3,6 and 9 post-transplant) were analyzed using both the nonlinear mixed-effect modeling (NONMEM) and nonparametric adaptive grid (NPAG) approaches, based on a two-compartment model with first order lagged time absorption and first order elimination. The predictive performance of the two models was evaluated in a separate group of 32 patients. Higher mean population parameter values and ranges of individual pharmacokinetic parameters were obtained with NPAG, especially for the elimination constant ke: mean 1.16 h(-1) (0.26-4.33 h(-1)) and 0.78 h(-1) (0.66-1.15 h(-1)) with NPAG and NONMEM, respectively. With NPAG, the skewness and kurtosis values for ke (2.03 and 7.80, respectively) were far from the theoretical values expected for normal distributions. Such a non-normal distribution could explain the high value of shrinkage (35%) obtained for this parameter with the parametric NONMEM method. Bayesian forecasting of mycophenolic acid exposure using the NPAG population pharmacokinetic parameters as priors yielded a better predictive performance, with a significantly smaller bias than with the NONMEM model (-1.68% vs -9.53%, p < 0.0001). In conclusion, in the present study. NPAG was found to be the most adequate population pharmacokinetic method to describe the pharmacokinetics of MPA in pediatric renal transplant recipients. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:216 / 224
页数:9
相关论文
共 50 条
  • [1] Population pharmacokinetics of mycophenolic acid in kidney transplant pediatric and adolescent patients
    Payen, S
    Zhang, D
    Maisin, A
    Popon, M
    Bensman, A
    Bouissou, F
    Loirat, C
    Gomeni, R
    Bressolle, E
    Jacqz-Aigrain, E
    THERAPEUTIC DRUG MONITORING, 2005, 27 (03) : 378 - 388
  • [2] Population Pharmacokinetics of Mycophenolic Acid in Renal Transplant Recipients
    Reinier M. van Hest
    Teun van Gelder
    Arnold G. Vulto
    Ron A. A. Mathot
    Clinical Pharmacokinetics, 2005, 44 : 1083 - 1096
  • [3] Population pharmacokinetics of mycophenolic acid in renal transplant recipients
    van Hest, RM
    van Gelder, T
    Vulto, AG
    Mathot, RAA
    CLINICAL PHARMACOKINETICS, 2005, 44 (10) : 1083 - 1096
  • [4] Population pharmacokinetics of mycophenolic acid and its metabolites in renal transplant patients.
    Sam, W
    Akhlaghi, F
    Rosenbaum, S
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P47 - P47
  • [5] Mycophenolic acid population pharmacokinetics in Tunisian renal transplant recipients
    Gaies, E.
    El Jebari, H.
    Jebabli, N.
    Salouage, I.
    Trabelsi, S.
    Charfi, R.
    Lakhal, M.
    Klouz, A.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2013, 27 : 70 - 70
  • [6] Population pharmacokinetics of mycophenolic acid in kidney transplant patients
    Eljebari, H.
    Jebabli, N.
    Gaees, E.
    Salouage, I.
    Trabelsi, S.
    Hamza, I.
    Aouichri, M.
    Lakhal, M.
    Klouz, A.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2010, 24 : 57 - 57
  • [7] Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients
    Le Guellec, C
    Bourgoin, H
    Büchler, M
    Le Meur, Y
    Lebranchu, Y
    Marquet, P
    Paintaud, G
    CLINICAL PHARMACOKINETICS, 2004, 43 (04) : 253 - 266
  • [8] Population Pharmacokinetics and Bayesian Estimation of Mycophenolic Acid Concentrations in Stable Renal Transplant Patients
    Chantal Le Guellec
    Hélène Bourgoin
    Matthias Büchler
    Yann Le Meur
    Yvon Lebranchu
    Pierre Marquet
    Gilles Paintaud
    Clinical Pharmacokinetics, 2004, 43 : 253 - 266
  • [9] Population pharmacokinetics of mycophenolic acid and its determinants in renal transplant recipients
    van Hest, RM
    van Gelder, T
    Vulto, AG
    Mathôt, RAA
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 (01) : 106 - 107
  • [10] PHARMACOKINETICS OF MYCOPHENOLIC ACID IN PEDIATRIC RENAL TRANSPLANT RECIPIENTS RECEIVING ORALMYCOPHENOLATE MOFETIL
    Cornelissen, Elisabeth A. M.
    Schreuder, Michiel
    Jacobs, Bart
    Aarnoutse, Rob
    Bruggemann, Roger
    PEDIATRIC NEPHROLOGY, 2012, 27 (09) : 1823 - 1824